NCT05634876 - UB-312 in Patients With Synucleinopathies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

February 11, 2025

Study Completion Date

February 11, 2025

Conditions

Multiple System AtrophyParkinson Disease

Interventions

BIOLOGICAL

UB-312 Injection

UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.

BIOLOGICAL

Placebo Injection

Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER